Fifty-six (45.9%) NSCLC patients with EGFR mutation were observed among the 122 NSCLC patients, including 27 (48.2%) cases of exon 19 deletions (19Del), 24 (42.9%) cases of exon 21 mutation (L858R), 3 (5.3%) cases of exon 21 mutation (L861Q) and 2 (3.6%) cases of S768I mutation in exon 21. This evidence concerns the gene EGFR and non-small cell lung carcinoma.